Anzeige
Mehr »
Donnerstag, 15.05.2025 - Börsentäglich über 12.000 News
Verpasst du gerade die Buffett-Aktie der neuen Generation?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1412H | ISIN: US00461U1051 | Ticker-Symbol: 8AT
Tradegate
14.05.25 | 14:04
1,099 Euro
+3,53 % +0,038
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
ACLARIS THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
ACLARIS THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,0401,06016:27
1,0411,06016:21

Aktuelle News zur ACLARIS THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiH.C. Wainwright cuts Aclaris stock price target to $161
FrAclaris Therapeutics, Inc.: Aclaris Therapeutics to Participate in the HC Wainwright "HCW@Home" Series1
08.05.Aclaris Therapeutics, Inc. - 10-Q, Quarterly Report1
08.05.Aclaris Therapeutics GAAP EPS of -$0.12, revenue of $1.46M1
ACLARIS THERAPEUTICS Aktie jetzt für 0€ handeln
08.05.Aclaris Therapeutics, Inc. - 8-K, Current Report1
08.05.Aclaris Therapeutics, Inc.: Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update53- Multiple Catalysts in Immuno-Inflammatory Indications Anticipated in 2025 and 2026 - - Expected Cash Runway Extended Through the First Half of 2028 - - Phase 2 Results Received to Date from Chinese...
► Artikel lesen
29.04.Aclaris Therapeutics Appoints Jesse Hall As CMO-
29.04.Aclaris Therapeutics appoints new Chief Medical Officer2
29.04.Aclaris Therapeutics, Inc.: Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer114WAYNE, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory...
► Artikel lesen
22.04.Aclaris Therapeutics gets FDA nod to begin trial of ATI-0521
22.04.Aclaris Therapeutics Announces Clearance Of ATI-052 IND By FDA2
22.04.FDA erteilt Aclaris Zulassung für klinische Studie mit neuem Medikament2
22.04.Aclaris Therapeutics, Inc.: Aclaris Therapeutics Secures U.S. Food and Drug Administration IND Clearance for ATI-052, Enabling Advancement of its Novel Bispecific Anti-TSLP/IL-4R Investigational Antibody74- Initiation of Upcoming Phase 1a/1b Clinical Trial Expected in the Second Quarter of 2025 - WAYNE, Pa, April 22, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage...
► Artikel lesen
28.02.Aclaris Therapeutics plans $300M mixed shelf offering2
27.02.Aclaris Therapeutics, Inc. - 10-K, Annual Report-
27.02.Aclaris Therapeutics GAAP EPS of -$1.01 misses by $0.78, revenue of $9.21M beats by $2.17M2
27.02.Aclaris Therapeutics, Inc. - 8-K, Current Report-
12.02.Aclaris Therapeutics, Inc.: New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK34
30.01.Aclaris Therapeutics forms new Scientific Advisory Board5
30.01.Aclaris Therapeutics, Inc.: Aclaris Therapeutics Announces Formation of New Scientific Advisory Board2
Seite:  Weiter >>
44 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1